Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Overview

Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 28, 2028

Arms, Groups and Cohorts

  • Stage IA-IIA cutaneous T cell lymphoma
  • Stage IIB and above cutaneous T cell lymphoma
  • CD30+ lymphoproliferative disorders
  • Plaque psoriasis with BSA>5% on routine phototherapy
  • Moderate to severe atopic dermatitis on routine bleach bath
  • Healthy controls

Clinical Trial Outcome Measures

Primary Measures

  • Bacterial diversity index
    • Time Frame: 3 months
    • Diversity analysis of microbiome samples (measured by number of bacteria species/sample)

Participating in This Clinical Trial

Inclusion Criteria

  • Group 1: Patients with stage IA-IIA cutaneous T cell lymphoma – Group 2: Patients with stage IIB and above cutaneous T cell lymphoma – Group 3: Patients with CD30+ lymphoproliferative disorder including lymphomatoid papulosis and cutaneous anaplastic large cell lymphoma – Group 4: Patients with plaque psoriasis with BSA>5% on routine phototherapy per standard of care – Group 5: Patients with moderate to severe atopic dermatitis on routine bleach bath therapy per standard of care – Group 6: Healthy individuals without the above skin conditions, similar age and sex distribution to the patients with cutaneous T cell lymphoma – All Groups: subjects who are age 18-89 years of age at time of enrollment – All Groups: Subjects who are able and willing to give informed consent for this study and the Dermatology Tissue Acquisition and Biorepository (STU00009443). Exclusion Criteria:

  • All Groups: Subjects who are younger than 18 years of age or older than 90 years of age – All Groups: Subjects who are unable to give consent – Patients currently on systemic antibiotics or recent (within past 4 weeks) exposure to systemic antibiotics – We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 89 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Northwestern University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Xiaolong (Alan) Zhou, Principal Investigator – Northwestern University
  • Overall Official(s)
    • Alan Zhou, MD, Principal Investigator, Northwestern University
  • Overall Contact(s)
    • Dermatology CTU, 312-503-5944, NUderm-research@northwestern.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.